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Background:Anticoagulation therapy is essential in atrial ﬁbrillation (AF), and in Japan, less intense control
is popular.
Purpose: To assess the efﬁcacy and safety with a special reference to low intensity warfarin therapy.
Subjects and methods: In 488 out of 508 patients with non-valvular AF, prothrombin time-international
normalized ratio (PT-INR) was kept at 1.6–2.59, and they were followed for 49.5 months: 2098 person-
years. The mean age was 73.7±9.9 years and 62% were male. The patients were divided by age:
≥70 years and <70 years, and by the intensity of warfarin therapy: PT-INR at 1.6–1.99 and at 2.0–2.59,
respectively. The clinical data andevent rates, ischemic stroke andmajor bleeding,were comparedamong
the subgroups.
Results: Heart failure, previous stroke, and higher CHADS2 score were more often reported in patients
≥70 years while males were involved more often as younger patients. A total of 166 of 339 patients
≥70 years and 69 of 149 patients <70 years belonged to the low intensity group.
Ischemic stroke and major bleeding occurred in 1.47%/year and 1.27%/year, respectively but there was
no difference between the two age groups and between the two intensities of warfarin therapy. Time in
therapeutic range was a predictor for ischemic stroke. A fall of PT-INR to <1.6 was found in 41.9% with
ischemic stroke and a rise >2.61 in 40.0% with major bleeding at the time of the events. Blunt trauma and
concomitant use of antiplatelets were risks for intracranial hemorrhage in the patients ≥70 years.
Conclusions: The event rates were similar between the low- (1.6–1.99) and high- (2.0–2.59) intensity
warfarin therapy groups in aged patients: <70 years and ≥70 years. Time in therapeutic range and a
transient fall or rise in PT-INR were risks for clinical events. Blunt head trauma and concomitant use of
antiplatelets were risks for intracranial hemorrhage.
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Introduction
Atrial ﬁbrillation (AF) is common sustaining arrhythmia and is
associated with increased morbidity and mortality mainly from
ischemic stroke/systemic embolism, and their prevention is essen-
tial [1–3]. New oral anticoagulant drugs have become available
and can be used relatively easily [4–6] while warfarin therapy
has been employed with some limitations; a narrow therapeu-
tic window, variable and unpredictable pharmacokinetic and
llege of Cardiology.
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harmacodynamic properties, and restriction of vitamin K intake.
precise monitoring is mandatory by checking prothrombin
ime-international normalized ratio (PT-INR). However, warfarin is
nexpensive and has been proved to be effective for the prevention
f ischemic stroke/systemic embolism in AF patients [7,8].
As the target level, PT-INR at 2.0–3.0 was recommended
n Western countries [8–10], but in Japan [11], patients aged
70 years (y) are recommended to be treatedwith less intensity: at
.6–2.59 based on previous secondary prevention studies [12,13].
owever, many Japanese physicians tend to treat AF keeping PT-
NR at 1.6–2.59 even in those with age <70y, and its rationale is to
e established.
In this study, we determined the PT-INR levels from all mea-
urements during 5 years’ follow-up at our clinic. Then, the event
ates, ischemic stroke/systemic embolism and hemorrhage were
ompared in relation to the intensity of PT-INR in the patients
7 y and <70y. At the times of clinical events, PT-INR and
ackgrounds were checked. The effects of concomitant use of
ntiplatelets on the event rates were also assessed.
atients and methods
atient characteristics
This is a retrospective study performed to assess the status of
arfarin therapy in our hospital (Tachikawa General Hospital), and
mong 3000 patients who were under warfarin therapy for non-
alvular AF in 2007. We completed analysis of the clinical and
ollow-up data for 5 years in 508 patients.
AF was diagnosed on electrocardiogram, and patients with
itral stenosis or prosthetic valve(s) were excluded from the
resent study. Cardiomyopathy or previous myocardial infarc-
ion with heart failure of more than moderate severity were also
xcluded. Obesity, hypertension, and diabetes mellitus were diag-
osed according to guidelines [14–16]. The concomitant diseases
ere diagnosed if the patients were taking medication for them.
The target therapeutic levels of PT-INR was guided according to
he JapanguidelineofAF therapy: PT-INR levelwas set at 2.0–3.0 for
he patientswith age <70y and at 1.6–2.59 for thosewith age ≥70y
11]. However, depending on the judgments of attending doctors,
atients <70y might be treated with lower intensity than recom-
ended: at 1.60–1.99 of PT-INR. If needed, antiplatelet agentswere
iven together with warfarin.
ata analysis
The patients were divided into two groups by the age at 2007:
70y and <70y. From the whole measurements of PT-INR in
hese 5 years, patients with a mean PT-INR kept at 1.6–2.59 were
hosen, and the patients were further divided into two groups:
hose treated at 1.60–1.99 and 2.0–2.59 of PT-INR: low- and high-
ntensity group, respectively.
able 1
linical characteristics of the patients.
All (n=488) ≥70 y
Age, mean± SD (years) 73.7±9.9 79.0
Male, n (%) 303 (62) 194 (5
Heart failure, n (%) 169 (35) 129 (3
Diabetes mellitus, n (%) 125 (26) 75 (2
Hypertension, n (%) 310 (64) 221 (6
Stroke/TIA, n (%) 118 (24) 93 (2
Antiplatelet, n (%) 94 (19) 62 (1
CHADS2, mean± SD 2.2±1.3 2.6
TTR, mean± SD 75.2±18.1 79.1
, number of patients; TIA, transient ischemic attack; TTR, time in therapeutic range.
* Comparisons between the two age groups.iology 64 (2014) 127–132
The patients were followed to the endpoints of clinical events,
transfer to other hospitals, death, or the completion of 5 years’
follow up. CHADS2 score [17], and time in therapeutic range (TTR)
[18] were compared among the subgroups. When clinical events
occurred, PT-INR at the time of event was measured, and com-
paredwith themeanPT-INRandTTR, andprecipitating factorswere
evaluated [19].
Deﬁnitions
Stroke was deﬁned as a sudden onset of non-convulsive and
focal neurologic deﬁcits persisting for >24h, and stroke was then
classiﬁed as either hemorrhagic or ischemic based on computed
tomography or magnetic resonance scanning. Systemic embolism
was deﬁned as an acute vascular occlusion of the extremities or
any organ. Intracranial hemorrhage included intra-cerebral hem-
orrhage (ICH), epidural, subdural, and subarachnoid hemorrhage.
The diagnosis was performed by a neurosurgeon (H.A.).
Major bleeding was deﬁned as that with a reduction in the
hemoglobin level ≥2g/L, transfusion of at least 2 units of blood,
or symptomatic bleeding in a critical area or organ. All other bleed-
ings which needed no supportive therapy were considered minor,
and were not analyzed.
Statistical analysis
The numerical values are presented as mean± SD and
categorical variables are presented in absolute numbers or per-
centage. The differences between groups were analyzed by
Mann–Whitney–Wilcoxon test for continuous variables and Pear-
son’s chi-squared test for categorical variables. Theevent rateswere
assessed with the use of actuarial curves, and Hazard ratios from
Cox proportional-hazards models in each subgroup. The indepen-
dent predictors of ischemic events were studied by a multivariate
analysis. Statistical Package for the Social Sciences (SPSS) version
12.0 (SPSS Inc., Chicago, IL, USA) was used and a two-sided p<0.05
was considered statistically signiﬁcant. This historical prospective
studywas approvedby the Institutional ReviewBoardof Tachikawa
Medical Center.
Results
Clinical proﬁles
Of 508 patients on warfarin therapy, the mean PT-INR was kept
within 1.6–2.59 in 488 (96.1%) patients, and none was treated
at >3.0. The subsequent analyses were performed in these 488
patients.
The clinical features are summarized in Table 1. Males were
dominant. They had concomitant diseases in 24–64%, and CHADS2
score was 2.2±1.3. Ninety four patients (19%) had adjunct
ears (339) <70 years (149) p-Values*
±5.6 61.6±6.5 <0.001
7) 109 (70) 0.001
8) 40 (26) 0.017
2) 50 (32) 0.008
5) 89 (57) 0.248
7) 25 (16) 0.011
8) 32 (21) 0.506
±1.3 1.5±1.1 <0.001
±16.0 73.5±20.2 0.412
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versus 74.8±10.0 years (p=0.003).
The TTR, CHADS2 score, and HAS-BLED score in the patients
with intracranial bleeding were 70.8±19.7%, 2.76±1.34, and
T
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ntiplatelet therapy for coronary artery disease, stroke, transient
schemic attack (TIA), or peripheral arterial disease.
Of these, 339 (69.5%) were ≥70y and 149 (30.5%) were <70y.
ale gender and diabetes mellitus were more common in the
ounger group while heart failure and stroke/TIA was found more
ften in the patients ≥70y. The CHADS2 score was higher in the
ged patient group (p<0.001). Antiplatelet therapy was employed
imilarly in the two age groups.
tatus of anticoagulation
Totally, the mean PT-INR was at 1.60–1.99 in 235 patients, and
as at 2.0–2.59 in 253: the mean PT-INR values were 1.89±0.08
nd 2.16±0.15, respectively. In the patients ≥70y, 166 of 339were
reated at low intensity while 69 of 149 patients <70y were treated
lso at low intensity (Table 2). TTR for those treated within 1.6–2.6
f PT-INRwas75.2±18.1% in all: 73.5±20.2% for thepatients≥70y
nd 79.1±16.0% for those <70y, respectively.
There was no signiﬁcant difference in the clinical data between
he patients treated at high versus low intensity except for the
revalence of hypertension in the younger group and TTR in the
ged group (Table 2).
schemic events
The patients were followed for 49.5 months on average: 2098
erson-years; for 47.6 months in the patients ≥70y and for
5.9 months in the patients <70y, respectively. Ischemic stroke
ccurred in 1.47%/year in all: 1.63%/year in the patients ≥70y and
.29%/year in the patients <70y, respectively without signiﬁcant
ifference (p=0.727).
In the patients ≥70y, the rate of ischemic stroke was not differ-
nt between low- and high-intensity therapy (Figs. 1 and 2). The
linical data were similar in the two subgroups (Table 2).
In the patients <70y, ischemic events tended to be higher with
ow-intensity therapy, but non-signiﬁcantly: 1.87%/year versus
.80%/year (p=0.201) (Figs. 1 and 2). Hypertension was more
requent in those on low-intensity therapy than those on high-
ntensity therapy (Table 2).
The multivariate analysis (Table 3) revealed that TTR was a
isk for ischemic events (odds ratio 2.898, 95% CI 1.283–6.545,
= 0.010). This was due to the difference in the patients
70y: 61.8±26.4 versus 74.1±19.6 (p=0.009), but not for
he younger patients: 74.5±21.0 versus 79.4±15.6 (p=0.376)
Table 2).
The mean PT-INR was not different between the patients with
nd without stroke: 2.01±0.18 versus 2.03±0.19 (p=0.662), but
t the time of admission for ischemic stroke, the PT-INR was lower
ompared to the mean PT-INR of other times: 1.64±0.46 versus
.01±0.18 (p<0.001), and was under the lower limit (<1.6) in 13
f 31 patients (41.9%).
able 2
he subgroups of the patients on warfarin according to the age and the targeted PT-INR.
≥70 years Low INR/High INR p
Male, n (%) 100 (60)/94 (54)
Heart failure, n (%) 65 (39)/64 (37)
Diabetes mellitus, n (%) 37 (22)/38 (22)
Hypertension, n (%) 105 (63)/116 (67)
Stroke, n (%) 42 (25)/51 (30)
CHADS2, mean± SD 2.5±1.4/2.6±1.2
PT-INR, mean± SD 1.89±1.4/2.6±1.2 <
TTR, mean± SD 61.8±26.4/74.1±19.6
, number of patients; PT-INR, prothrombin time-international normalized ratio; TTR, tim
* Comparisons between two intensities in each age group.iology 64 (2014) 127–132 129
Hemorrhagic events
During the follow-up period, major bleeding occurred in 5.33%
(n=26): 1.27%/year: 0.89%/year and 1.63%/year for intra- and
extracranial bleeding in the patients ≥70y, and 0.14%/year and
0.58%/year in the patients <70y, respectively. There was no
signiﬁcant difference in hemorrhagic events between low- and
high-intensity therapy in the two age groups (Fig. 1). Of 14 cases
of intracranial bleeding, 5 were ICH, 3 were subarachnoid hemor-
rhage, 4 were subdural, and 1 was epidural hemorrhage. One had
hemorrhage of metastatic brain tumor. In 3 of 5 patients: 1 epi-
and 2 subdural hematoma, bleeding was considered to be related
to blunt head trauma. The major extra-cranial bleeding was from
gastrointestinal tract (n=10), or in the thigh (n=2). Blunt trauma
to thigh was observed in two patients.
The mean PT-INR and TTR were not different between the
patients with and without major bleeding: 2.01±0.20% versus
2.03±0.19% and 75.3±20.4% versus 75.5±19.1%, respectively. In
the two age groups, TTR was not different between the patients
with and without major bleeding: 74.9±20.2% versus 74.9±20.1%
for ≥70y (p=0.752) and 77.2±20.6% versus 79.2±15.9% for <70y
(p=0.792). For intracranial bleeding, TTR was again not different
between low- and high-intensity therapy in the two age groups
ranging from 73.3% to 80.1%.
The age was higher in the patients with ICH than those with
epidural, subdural, and subarachnoid hemorrhage: 78.4±8.6 yearsFig. 1. Event rates in the two age groups at two intensities of warfarin therapy (high
and low). Ischemic stroke, major bleeding, or intracranial hemorrhage were not
different in the two age groups: ≥70 years (A) and <70 years (B). INR, international
normalized ratio.
-Values* <70 years Low INR/High INR p-Values*
0.272 51 (74)/58 (73) 0.846
0.682 16 (23)/24 (30) 0.350
0.942 28 (41)/22 (28) 0.090
0.463 49 (71)/40 (50) 0.009
0.389 13 (19)/12 (15) 0.532
0.706 1.7±1.2/1.4±1.1 0.061
0.001 1.89±0.07/0.15±0.13 <0.001
0.009 74.5±21.0/79.4±15.6 0.375
e in therapeutic range.
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Fig. 2. The cumulative event rate during warfarin therapy. There was no signiﬁcant diffe
Ischemic stroke (right), major (middle), and intracranial bleeding (right) in the patients ≥7
ratio.
Table 3
The multivariate analysis for ischemic events.
p-Value Odds ratio 95% CI p-Value
Age (<70 years) 0.151 0.515 0.205–1.297 0.159
Gender (male) 0.1999 0.206 0.330–1.510 0.3680
CHF 0.5730 1.220 0.584–2.550 0.5970
Hypertension 1.000 1.200 0.552–2.600 0.6480
Diabetes mellitus 0.0959 0.359 0.122–1.060 0.0628
Previous stroke 0.2100 1.510 0.704–3.250 0.2890
CHADS2 0.616 1.2631 0.550–2.760 0.613
PT-INR 0.579 1.232 0.589–2.580 0.579
TTR 0.011 2.898 1.283–6.545 0.010
Comparisons for age (<70 years versus ≥70 years), for CHADS2 (0–1 versus ≥2), PT-
INR (1.60–1.99 versus 2.0–2.59), and TTR (≥66.5% versus <66.5%).
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IHF, chronic heart failure; PT-INR, prothrombin time-international normalized
atio; TTR, time in therapeutic range.
.04±0.65, and not different from the others. PT-INR at the time of
ntracranial hemorrhagewas not different from themean PT-INR of
ther times: 2.08±1.28 (p=0.715), but 2 patients had PT-INR>2.6:
.79 and 4.98, respectively. The causes of rise in PT-INR were
owever, not apparent.In the patients with intracranial bleeding, blood pressure
n the preceding three visits was good 127±18/67±13mmHg
systolic/diastolic), but 4 of 14 had blood pressure ≥140mmHg:
40–160mmHg.
able 4
ombined use of warfarin and antiplatelets in the two age groups.
≥70 years Antiplatelet +/− p-
Male, n (%) 43 (67)/152 (55) 0
Heart failure, n (%) 26 (41)/103 (38) 0
Diabetes, n (%) 17 (27)/58 (21) 0
Hypertension, n (%) 47 (73)/174 (63) 0
Stroke, n (%) 27 (44)/65 (24) 0
CHADS2 score± SD 3.1±1.2/2.4±1.3 <0
Events
Ischemic stroke, % 0.79/1.83 0
Major bleeding 3.17/1.28 0
ICH, % 2.37/0.73 0
CH, intra-cerebral hemorrhage.
* Comparisons between with and without antiplatelet therapy in each age group.rence in the events in the two age groups and two intensities of warfarin therapy.
0 years (upper) and in the patients <70 years (lower). INR, international normalized
Antiplatelet therapy and events
Ninety six patients received concomitant antiplatelet therapy:
aspirin (n=75), ticlopidine (n=20), cilostazol (n=6), or sarpogre-
late (n=1). Diabetes mellitus and hypertension were found more
often in the younger group, and CHADS2 scores were higher in
the patients treated with antiplatelet therapy in both age groups
(Table 4).
Intracranial hemorrhage occurred more often in the patients
≥70y with antiplatelets compared to those without: 2.37%/year
versus 0.73%/year (Fig. 3).
Discussion
In our hospital, the mean PT-INR values were kept within
1.6–2.59 in 96.1% of patients, and a half of the patients <70y
had been treated less intensively than that recommended by the
guideline. However, the event rates were not different between
the patients treated with low- and high-intensity warfarin ther-
apy in the two age groups: <70y and ≥70y. Ischemic stroke might
be related to transient fall of PT-INR, and TTR can be a predictor.
Bleeding might be related to a rise in PT-INR, and blunt trauma or
concomitant use of antiplatelets can be precipitating.
The number of AF patients is growing in Japan, and this must be
due to an increase in the number of aged people and/or risk factors
Value <70 years Antiplatelet +/− p-Values*
.117 25 (78)/84 (72) 0.473
.683 10 (31)/30 (26) 0.525
.439 17 (53)/33 (28) 0.008
.099 26 (81)/63 (54) 0.005
.001 7 (22)/18 (15) 0.382
.001 2.1±1.1/1.4±1.1 0.002
.266 0.66/1.47 0.446
.068 0/0.18 0.233
.034 0/0.74 0.600
K. Takarada et al. / Journal of Cardiology 64 (2014) 127–132 131
F dmaj
t ntly i
f
t
e
d
a
v
E
t
w
i
s
H
P
[
p
H
t
t
t
p
ﬂ
i
a
w
o
f
i
T
n
a
<
s
o
a
w
aig. 3. The events and antiplatelet therapy. Ischemic events (left upper and lower) an
herapy as without in the two age groups. Intracranial bleeding was higher signiﬁca
or AF development [20,21]. To reduce morbidity and mortality of
he AF patients, anticoagulation therapy is essential [8–10]. How-
ver, a substantial number of patients used to be untreated in Japan
ecades ago [22] and possibly even now [23], but this situation
ppears to be rapidly changing, and 87.3% of patients with non-
alvular AF are now receiving anticoagulation therapy [24–27].
mployment of anticoagulation therapy has now accelerated with
he introduction of oral anticoagulation agents [28].
Ischemic stroke occurred at 1.47%/year in the present study
hen the mean PT-INR was kept at 1.6–2.59. Ischemic episodes
n the patients <70y with less intensive warfarin therapy occurred
imilarly as those treated as recommended by the guideline [11].
owever, the rationale to treat the younger patients at 1.6–2.0 of
T-INR should be evaluated in a large number of the patients.
The adequacy of warfarin therapy is now evaluated by TTR
18,29–36]. In a multicenter study [36], Okumura et al. reported
oor TTR in the AF patients <70y: 46±23% in Japanese patients.
owever, it was simply due to the fact that physicians are treating
he patients less intensively from a fear of hemorrhagic complica-
ions. TTRwas lower in thepatientswith ischemic events compared
o those without, especially in the patients ≥70y (p=0.009), and a
redictor of ischemic stroke (Tables 2 and 3).
A lower TTR value in spite of similar mean PT-INR would mean
uctuation of PT-INR, and actually, PT-INR was lower at the time of
schemic stroke, and 41.9% of the patients showed PT-INR<1.59 on
dmission. For the fall in PT-INR, multiple factors must be involved
hich would include poor compliance, diets, concomitant drugs,
r liver dysfunction. Poor compliance prior to ischemic events was
elt most likely. Although TTR can be a good marker, a transient fall
n PT-INR during anticoagulation therapy might be not reﬂected in
TR [37].
Major bleeding occurred at a rate of 1.27%/year, and there was
o difference in the incidence of major bleeding between the low-
nd high-intensity therapy and in the two age groups: ≥70y and
70y.
To predict hemorrhagic events during anticoagulation therapy,
everal factors have been established as risks [19,38–40]. In a sec-
ndary prevention study, Toyoda et al. have shown that systolic
nd diastolic blood pressure levels were independently associated
ith development of ICH, and blood pressure130/81mmHg was
risk [40].or bleeding (middle upper and lower) occurred similarlywith the use of antiplatelet
n the patients ≥70 years (right upper), but not in the younger group (right lower).
In the present study, 2 (14.3%) of 14 patients showed PT-INR
exceeding 2.6 at the time of intracranial hemorrhage. Although
mean blood pressure in the preceding three visits was well con-
trolled, 4 (28.6%) had blood pressure ≥140mmHg which can be a
risk for intracranial bleeding. Furthermore, blunt head trauma was
suggested as a risk for intracranial bleeding as it occurred in 3 of
5 patients with intracranial bleeding.
As reported previously [41–43], a combination of warfarin and
antiplatelet therapy was associated with intracranial hemorrhage
in the aged patients. Whether such intracranial bleeding can be
prevented by new oral anticoagulant drugs is to be determined
[44–46].
Limitations
The study is a relatively small, historical prospective study of
2098 person-years in a single center. However, the results were
compatible with those of old and recent reports for the patients
aged ≥70y [26,34,35]. For the younger patients, a study in a large
numberof patientswouldbedesired [26]. A largemulticenter study
is becoming available in this country, but a small study like the
present one may have some merits in analyzing the clinical back-
grounds and precipitating causes at the time of clinical events.
Conclusions
PT-INR and TTR were well controlled, but a half of patients
<70 yearswere treated less intensively at 1.60–1.99 of PT-INRwith-
out signiﬁcant increase in ischemic stroke. TTR was a predictor of
ischemic stroke, and transient fall in PT-INR, poor blood pressure
control, or blunt trauma can be risks for clinical events.
Disclosure
None.Acknowledgment
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